Biosimilar Labeling: Should FDA Just Throw Up Its Hands And Finalize Guidance?
Brand and generic industries are on opposite sides of spectrum on most issues; there is mutual opposition, however, to the use of a meaningless four-letter suffix in the proper name of a product.
You may also be interested in...
Switching, manufacturing, and indication extrapolation among worries raised in closed-door session where AbbVie argued Humira's mechanism of action is not entirely understood.
A biosimilar that is not licensed for all of the indications on a reference product's label may still need to include some information about that off-label indication to ensure safe use, draft guidance says.
Data developed to show no clinically meaningful differences with the reference product could confuse prescribers, agency says in new draft guidance.